Use of baricitinib in treatment of COVID-19: a systematic review.

Sampath, Ananyan; Banerjee, Aditya; Atal, Shubham; Jhaj, Ratinder

Sampath, Ananyan; Banerjee, Aditya; Atal, Shubham; Jhaj, Ratinder.

Afiliação

Sampath A; Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.
Banerjee A; Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.
Atal S; Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.
Jhaj R; Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.

Med Res Rev ; 43(5): 1322-1345, 2023 09.

Article em En | MEDLINE | ID: mdl-36951224

Assuntos

COVID-19; Sulfonamidas/uso terapêutico; COVID-19/terapia; Tratamento Farmacológico da COVID-19; SARS-CoV-2; Resultado do Tratamento; Humanos

Palavras-chave

COVID-19; JAK kinase inhibitor; SARS-Cov-2; baricitinib; clinical outcome; mortality

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Prognostic_studies / Qualitative_research / Systematic_reviews Limite: Humans Idioma: En Revista: Med Res Rev Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Índia

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google